The Cystic Fibrosis Foundation has joined 11 other patient groups in filing an amicus brief to challenge the short-term, limited-duration health insurance rule, which threatens access to adequate, affordable coverage for people with cystic fibrosis.
Site Search
Observational study supported by the CF Foundation will monitor real-world experience with Trikafta
Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. About 17% of individuals with CF who had Pseudomonas infections last year had multi-drug resistant strains.
The Cystic Fibrosis Registry Global Harmonization Group published in the Journal of Cystic Fibrosis updated data on the impact of COVID-19 on people with CF. The manuscript reports on 181 people with cystic fibrosis from 19 countries diagnosed with COVID-19.
Study reaffirms the Foundation's commitment to advance solutions to the growing challenge of antibiotic resistance and evaluate the use of phage to treat infections for people with CF
More than 160 organizations join the Cystic Fibrosis Foundation in asking Congress to expand paid family and medical leave for people with chronic conditions, such as cystic fibrosis.
A cystic fibrosis diagnosis must not disqualify an individual from life-saving care.
The letter to Senators Mitch McConnell and Orrin Hatch highlights the critical role that Medicaid plays in helping patients and consumers access adequate, affordable health insurance.
The Cystic Fibrosis Foundation announced a new set of research agreements to drive progress on its Path to a Cure. The nine awards will advance a variety of tools and strategies to accelerate treatments for the underlying cause of cystic fibrosis for all people with CF, regardless of their mutations.
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.